Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004731 · ClinicalTrials.gov registry record · Phase 2

Parkinson's Disease Treatment With Coenzyme Q10

A Phase 2 study of Parkinson's Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00004731 is a Phase 2 study of Parkinson's Disease that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004731, a Phase 2 study of Parkinson's Disease, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.

Conditions Studied

Interventions

  • DRUG Coenzyme Q10

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Start Date 1998-09
Est. Completion 2003-10
Phase Phase 2

What the Registry Record Tells You About NCT00004731

The ClinicalTrials.gov registry entry for NCT00004731 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Coenzyme Q10 is the first listed.

NCT00004731 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00004731 about?

NCT00004731 is a clinical study titled "Parkinson's Disease Treatment With Coenzyme Q10". The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.

What is the current status of trial NCT00004731?

This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2003-10.

What conditions does trial NCT00004731 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT00004731?

The interventions under investigation include: Coenzyme Q10 (DRUG).

Who is sponsoring clinical trial NCT00004731?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004731 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.